Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3561-3569

  Bilezikian, John P ^a   Brandi, Maria Luisa ^b   Eastell, Richard ^c   Silverberg, Shonni J ^a   Udelsman, Robert ^d   Marcocci, Claudio ^e   Potts, John T ^f  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PISA   (Italy)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALENDRONIC ACID; CALCITRIOL; CALCIUM; CINACALCET;

ALBUMIN BLOOD LEVEL; ASYMPTOMATIC DISEASE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CARDIOVASCULAR SYSTEM; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; HYPERCALCEMIA; KIDNEY; PARATHYROIDECTOMY; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKELETON; SPINE FRACTURE; THYROID SURGERY; TRABECULAR BONE; WORKSHOP; ASYMPTOMATIC DISEASES; CONSENSUS DEVELOPMENT; EDUCATION; ENDOCRINOLOGY; EVIDENCE BASED MEDICINE; HYPERPARATHYROIDISM, PRIMARY; STANDARDS;

ASYMPTOMATIC DISEASES; EDUCATION; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINES AS TOPIC;

EID: 84906689673     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1413     Document Type: Conference Paper

References (11)

1. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab. 2009;94:335-339.
2. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3570-3579.
3. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3580-3594.
4. Udelsman R, Åkerström G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3595-3606.
5. Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2014;99:3607-3618..
6. Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F. Development and use of FRAX in osteoporosis. Osteoporos Int. 2010;21:S407-S413.
7. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-58.
8. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
9. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005;90:2122-2126.
10. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-3470.
11. Lewiecki EM, Baim S, Langman CB, Bilezikian JP. The official positions of the International Society for Clinical Densitometry: perceptions and commentary. J Clin Densitom. 2009;12:267-271.